Home » Stocks » CYTK

Cytokinetics, Inc. (CYTK)

Stock Price: $28.93 USD 0.16 (0.56%)
Updated Aug 3, 2021 1:36 PM EDT - Market open
Market Cap 2.47B
Revenue (ttm) 58.55M
Net Income (ttm) -134.99M
Shares Out 71.20M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $28.93
Previous Close $28.77
Change ($) 0.16
Change (%) 0.56%
Day's Open 28.83
Day's Range 28.24 - 29.22
Day's Volume 492,288
52-Week Range 14.71 - 31.41

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 30, 2021 it granted stock options to purchase an aggregate of 258,75...

21 hours ago - GlobeNewsWire

Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Declineof SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo

1 day ago - GlobeNewsWire

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 days ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 11,500,00...

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 5, 2021 at 4:00 P...

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common ...

1 week ago - GlobeNewsWire

Cytokinetics Incorporated (NASDAQ: CYTK) shares continue to move forward after it announced positive REDWOOD-HCM Phase 2 data for CK-274 and garnered favorable comments from analysts. On Tuesday, Barcla...

1 week ago - Benzinga

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

2 weeks ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $200,000,000 of shares of ...

2 weeks ago - GlobeNewsWire

Today, Cytokinetics Incorporated (NASDAQ: CYTK) reported positive REDWOOD-HCM Phase 2 data showing CK-274 treatment for ten weeks resulted in substantial and statistically significant reductions in the ...

2 weeks ago - Benzinga

The company's new heart drug candidate produced encouraging clinical trial results.

2 weeks ago - The Motley Fool

CYTK stock is being boosted by bullish biopharma buyers today. The company is reporting with optimism regarding its newest HCM treatment.

2 weeks ago - InvestorPlace

Cytokinetics Incorporated (NASDAQ: CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274) in hypertrophic cardiomyopathy (HCM).  The Compan...

2 weeks ago - Benzinga

Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardi...

2 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2021 it granted stock options to purchase an aggregate of 90,000...

1 month ago - GlobeNewsWire

Further Analyses of GALACTIC-HF Supplement Previously Announced Data Regarding Increased Treatment Effect of Omecamtiv Mecarbil in Patients with More Severe Heart Failure Further Analyses of GALACTIC-HF...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at Heart Failure 2021, an International Congress of the Europe...

1 month ago - GlobeNewsWire

Top Line Results of METEORIC-HF Expected in Early 2022

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to parti...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in th...

2 months ago - GlobeNewsWire

Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF)....

2 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., May 16, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records relat...

2 months ago - GlobeNewsWire

Secondary Analysis From GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Secondary Analysis From GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session

2 months ago - GlobeNewsWire

Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.86% and -16.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Secondary Analysis from GALACTIC-HF  to be Presented in Late Breaking Clinical Trial Session at ACC.21

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE, an o...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 12, 2021 at...

2 months ago - GlobeNewsWire

Next Cohort to Enroll Patients on Background Therapy of Disopyramide Next Cohort to Enroll Patients on Background Therapy of Disopyramide

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2021 it granted stock options to purchase an aggregate of 69,800...

2 months ago - GlobeNewsWire

Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and develop skeletal sarcomere activators for diseases associa...

Other stocks mentioned: ALPMY
2 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2021 at 4:00 PM E...

3 months ago - GlobeNewsWire

Next-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposure Response and Pharmacokinetics to Enable Flexible Dose Titration Next-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposur...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to part...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discover...

4 months ago - GlobeNewsWire

Cytokinetics (CYTK) has moved higher as of late, but there could definitely be trouble on the horizon for this company

4 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pres...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 26, 2021 it granted stock options to purchase an aggregate of 9,...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28 it is joining the European Organisation for Rare Diseases (EU...

5 months ago - GlobeNewsWire

Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF

5 months ago - GlobeNewsWire

Appointment Adds to Board Expertise in Commercial Development and Market Access as Company Prepares for Further Corporate Development Appointment Adds to Board Expertise in Commercial Development and Ma...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 25, 2021 at 4:0...

5 months ago - GlobeNewsWire

Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 29, 2021 it granted stock options to purchase an aggregate of 13,...

6 months ago - GlobeNewsWire

Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designat...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to parti...

6 months ago - GlobeNewsWire

Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing Company is Planning Regulatory Inte...

7 months ago - GlobeNewsWire

Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS Additional Data from FORTITUDE-ALS Support Rationale...

7 months ago - GlobeNewsWire

Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left V...

7 months ago - GlobeNewsWire

Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patie nts with Lower Ejection Fraction

7 months ago - GlobeNewsWire

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, wh... [Read more...]

Industry
Biotechnology
IPO Date
Apr 29, 2004
CEO
Robert Blum
Employees
184
Stock Exchange
NASDAQ
Ticker Symbol
CYTK
Full Company Profile

Financial Performance

In 2020, Cytokinetics's revenue was $55.83 million, an increase of 107.79% compared to the previous year's $26.87 million. Losses were -$127.29 million, 4.60% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Cytokinetics stock is "Buy." The 12-month stock price forecast is 32.64, which is an increase of 12.82% from the latest price.

Price Target
$32.64
(12.82% upside)
Analyst Consensus: Buy